Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer

PURPOSE: Synergy is observed with the combination of capecitabine and docetaxel due to docetaxel mediated up-regulation of thymidine phosphorylase. A phase II trial was performed with the combination for metastatic, castrate resistant prostate cancer. MATERIALS AND METHODS: Eligible patients had met...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Vaishampayan, Ulka N., Marur, Shanthi, Heilbrun, Lance K., Cher, Michael L., Dickow, Brenda, Smith, Daryn W., Al Hasan, Samir A., Eliason, James
Формат: Artigo
Язык:Inglês
Опубликовано: 2009
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3869185/
https://ncbi.nlm.nih.gov/pubmed/19447430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2009.02.105
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы